Microglial over-activation plays a crucial roles during neuroinflammation. Aldose reductase (AR) is one of the enzymes that has been linked to inflammatory processes in several diseases. Therefore, inhibition of AR is considered as an important strategy to reduce inflammation. In the present study, Quercetin (Q) and monochloropivaloylquercetin (MCPQ) showed potent inhibition on AR expression and anti-neuroinflammatory effects in Amyloid β (Aβ) peptide (1-42) induced inflammatory process by inhibiting expression of inflammatory mediators from microglial cells. Furthermore, ablation of AR caused a significant reduction on COX2 expression in Aβ-induced neuroinflammation. Q and MCPQ suppressed COX2 mRNA and protein expression, which further resulted in downstream inhibition of prostaglandin E 2 (PGE 2 ) release in Aβ-induced neuroinflammatory process. Additionally, Aβ treatment resulted in activation of Mitogen Activated Protein Kinase (MAPK) and increased translocation of Nuclear Factor Kappa B (NFκB). Q and Sorbinil significantly reduced the activation of MAPK, at the same time Q, MCPQ and sorbinil decreased nuclear translocation of NFκB and diminished tumor necrosis factor (TNF)-α release in Aβ-induced neuroinflammation. The results suggested that AR is a probable target for treatment of neuroinflammation as well as Q and MCPQ could be effective agents for treating or preventing inflammation-related neurodegenerative diseases by AR inhibition.
In recent years, scientists have been interested in the role(s) of inflammation on neurodegenerative diseases [1] . In the central nervous system (CNS), the over-activation of microglia is considered to be a main cause of neuroinflammation. Once activated, microglia release proinflammatory factors, including nitric oxide (NO), PGE 2 , TNF-α, interleukin (IL)-1β, reactive oxygen species (ROS) at the sites of neuronal injury that hastens the neurodegenerative process [2, 3] . Since these mediators contribute to neuronal injuries and progressive neuroinflammatory diseases in the CNS [4, 5] , inhibition of microglial activation might be an effective therapeutic strategy to alleviate inflammation-related neurodegenerative diseases [6, 7] .
Aldose reductase (AR) is a cytosolic enzyme belonging to a superfamily of aldo-keto reductases. Aldo-keto reductases are NAD(P)H-dependent oxidoreductases that are best characterized as glucose reducing enzyme. AR is mainly involved in the conversion of glucose to sorbitol during glucose metabolism [8] . Recently, AR has been found to be closely related to inflammatory diseases such as endotoxemia, sepsis, allergic airway inflammation, uveitis and diabetes mellitus [9] [10] [11] [12] [13] . Moreover, AR inhibition blocks endotoxin-induced inflammation through the downregulation of various proinflammatory cytokines and chemokines, where orally bioavailable AR inhibitors were tested in airway inflammatory diseases, such as asthma [12] . Several studies in pharmacological inhibition of AR or genetic ablation of the AR has been shown to protect the cells from inflammation [14] [15] [16] [17] . However, evidence that AR is involved in the neuroinflammatory process over microgliamediated transcription and biosynthesis of proinflammatory cytokines is lacking. Therefore, pharmacological inhibition of AR or genetic ablation of AR appears to be an attractive therapeutic strategy for neuroinflammation and inflammation-related progressive dysfunction of neurons in CNS.
Given the recent developments in neuro-inflammation and related neurodegenerative diseases, new treatment approaches are being initiated. Perhaps one of the most promising hypothesis is related to Aldose Reductase enzyme activity as it has been shown to increase in neurodegenerative diseases. Several experimental studies that have been conducted in recent years suggest that the pharmacological inhibition of aldose reductase provided substantial improvement in inflammation related-neurodegenerative diseases [18, 19] .
Considerable attention has been devoted to the search for phytochemical therapeutics that are effective in neurodegenerative diseases. Flavonol quercetin is one of the most widely studied antiinflammatory natural compound which is also being extensively reviewed for its biological activities [20] . In plants, quercetin is present mainly in the form of O-glycosides, a sugar group, such as glucose, galactose, rhamnose, rutinose or xylose. The glycosidic structure has been shown to be relatively close to the biological activity and bioavailability of quercetin [21] . Patent databases present numerous semisynthetic derivatives of quercetin with multiple biological effects such as vasodilator, antidiabetic, antihistaminic, anticancer, immune supporting effect and others as well as, including their anti-inflammatory effect [22] .
Considering the pharmacological value of quercetin derivatives, it is apparent that as an aldose reductase inhibitor quercetin (Q) and one of its derivatives monochloropivaloylquercetin (MCPQ) should be investigated in a microglial neuroinflammation model. The inhibitory effect of aldose reductase on LPS-induced macrophage activation has been previously studied. [15] However, there is a lack of knowledge about the relationship between amyloid beta toxicity and aldose reductase activity as well as the molecular mechanisms that are related to the neuroinflammatory process in microglia cells. Until now, only one report has shown the anti-inflammatory effect of AR inhibitors on Aβ-induced microglial activation [23] . Apart from these studies, the anti-inflammatory effects of Q and MCPQ in murine BV-2 microglial cells in Aβ-induced inflammatory process in either chemically or siRNA inhibited AR conditions have been investigated. In order to accomplish this, the potential action of mechanism of AR inhibition with Q and MCPQ on MAPK activation, nuclear NFκB translocation, NO and PGE 2 levels and proinflammatory cytokines and COX2 and inducible nitric oxide synthase (iNOS) expressions in Aβ-induced BV-2 microglial cells.
According to the cytotoxicity results sorbinil was not toxic at any dose whereas Q and MCPQ were toxic over 10 µM (Figure 1 To test whether or not AR suppression is directly related to the inflammatory process in microglia cells, we have transfected the cells with Akr1b3 siRNA and in these cells COX-2 expression was reduced, but was not significant. However, when the inflammation was induced by β-amyloid peptide, the COX-2 expression was suppressed in AR transfected cells ( Figure 2B ). JNK, P38 and ERK are three major MAPK family members. Especially, ERK is extensively activated in microglia in early Alzheimer Disease [24] . Thus, the regulatory effect of AR inhibitors Sorbinil, Q and MCPQ on JNK, P38 and ERK MAPK activations was investigated. As shown in Figure 3 , Aβ is found to activate MAPK pathway in BV-2 cells and this induction was attenuated by Q by reducing the pERK/ERK and pP38/P38 ratio, especially at higher (10 µM) concentrations (p < 0,05). Except for the 20 µM sorbinil none of the compounds tested were effective in any concentration on JNK activity.
These results indicate that P38 and ERK MAPK inflammatory pathways are involved in Q-mediated microglial inactivation and neuroinflammation inhibition as AR inhibitors.
In neurodegenerative diseases, the inflammatory response is mediated by activated microglia which release pro-inflammatory mediators such as TNF-α, IF-γ to exacerbate these diseases [25] . As shown in Figure 4 , production of TNF-α by BV-2 microglia was significantly induced by Aβ treatment. (p < 0,05). The increased levels of TNF-α were significantly attenuated by all tested compounds (p < 0,05). Aβ-stimulation elicited an increase in Effect of quercetin derivatives in treating neurodegenerative diseases Natural Product Communications Vol. 13 (6) 2018 695 Figure 5 : Effect of Sorbinil, Q and MCPQ on iNOS, total nitrite-nitrate levels, COX2 and PGE 2 . The BV-2 cells were pre-incubated by sorbinil, Q and MCPQ for 3h and the Aβ is applied to cells for 24h. iNOS mRNA and COX2 mRNA were evaluated by Real Time-PCR and the protein expressions of iNOS and COX2 were determined by western blot. PGE 2 levels measured by using ELISA. Total nitrite-nitrate levels were measured spectrophotometrically. *: significantly different from control (p<0,05) and #: significantly different from Aβ group: p<0,05) (n=3).
IF-γ levels but this increase was not significant. Any alterations between the groups were not significant on IF-γ levels.
Q and MCPQ were shown to reduce NO production by inhibiting iNOS activity in LPS-induced BV-2 cells [26] . To investigate whether a similar effect could also be seen in Aβ-induced neuroinflammation in BV-2 cells, iNOS mRNA and protein expression and total nitrite-nitrate levels were measured. iNOS protein expression was increased by Aβ (5 µM) and it has reduced by Q and MCPQ in a concentration dependent manner. However these alterations were not significant and similar results were seen in iNOS mRNA and total nitrite/nitrate levels by Q and MCPQ ( Figure 5 ).
Stimulation with Aβ (5 µM) induced a remarkable expression of COX2 mRNA and protein levels (p<0,05). Both compounds tested caused a significant and concentration dependent decrease in even COX2 protein and mRNA expressions (p<0,05). The effects of Q and MCPQ were more potent than the Sorbinil ( Figure 5 ). The increased PGE 2 levels with Aβ (5µM) were significantly attenuated by both compounds and this effect was more subtle by Q (10µM) than MCPQ ( Figure 5 ).
NFκB is a key regulator for inducing the production of proinflammatory mediators [27] . The activation of NFκB is promoted by initial phosphorylation and degradation of IκB, which further leads to NFκB p65 subunit nuclear translocation and the transcription of inflammatory genes [28] . As shown in Figure 6 , it was discovered that the nuclear translocation of NF-κB p65 from the cytoplasm was increased by Aβ, which was markedly reversed by Sorbinil (40 μM) or Q and MCPQ (10-20 μM) in BV-2 cells, that suggested AR inhibitors could effectively inhibit NF-κB activation in Aβ-induced neuroinflammation ( Figure 6 ).
Aldose reductase is an enzyme responsible for the conversion of glucose to sorbitol through polyol pathway of glucose metabolism. During the past several decades, there have been extensive studies citing the involvement of AR in the pathophysiology of diabetic complications [9, 29] . However, by catalyzing the reduction of a wide array of substances including lipids, phospholipids, and steroids etc., the physiological function of AR is unlikely to be restricted to only glucose metabolism. More recent studies have demonstrated that AR inhibition could be an important therapeutic approach in terms of its anti-inflammatory effect in bacterial endotoxin induced sepsis [15] . After the invention of AR inhibition in anti-inflammatory therapies, the role of AR inhibitors have been further investigated in several inflammatory diseases such as ocular inflammatory disease, uveitis and airway inflammation has been investigated [10, 11, 30] . In addition, AR inhibition prevents NFκB dependent inflammatory signals induced by cytokines, growth factors and endotoxin revealing the crucial role of AR in inflammatory process [31] . Therefore, AR is becoming an attractive drug target for inflammation relevant diseases.
Neuroinflammation is a process followed by a neurodegeneration where an accumulation of glial cells or differential activation of microglia cells being one of the key pathways that regulates neuroinflammation [32] . The presence of activated microglia within injured brain regions and in post-mortem tissue from patients with various neurodegenerative diseases, has led to the initial assumption that all reactive microglia could contribute to an adverse and degenerative process [33, 34] . However, this makes an assumption that glial cells can be transformed into aggressive effector cells that can attack healthy neurons either physically, as by phagocytosis or via secreted factors including proinflammatory and antiinflammatory cytokines, NO, ROS, glutamate, and growth factors to damage surrounding neurons and accelerate neurodegenerative process [35] [36] [37] . There is an increasing interest to design and develop novel anti-inflammatory agents for neuroinflammation such as AR inhibitors. However, until now, there is only one report that has shown the anti-inflammatory effect of ARIs on Aβ specific neuroinflammation model, such as Aβ-induced microglial activation [23] . Quercetin has been chosen as one of the AR inhibitors [38, 39] since it has been investigated for its in vitro [40] and in vivo [41] inhibitory effects.
Taking into account the bioavailability of quercetin in in vivo studies, its potent derivatives have been investigated for AR inhibition over rat ocular sorbitol accumulation and MCPQ was found to be more effective than the Q [41] . Furthermore, Q and MCPQ has been shown to inhibit AR enzyme in LPS inducedneuroinflammation in BV-2 cells [26] . In that study antineuroinflammatory capability of MCPQ was assessed in BV-2 microglial cells. They revealed that treatment with MCPQ attenuated the production of the inflammatory mediators, NO and TNF-α in LPS-stimulated microglia somewhat more efficiently than quercetin. In consistence with the effects on proinflammatory markers, MCPQ and Q showed a downregulation of NFκB activation. This quercetin analogue also caused a decline in BV-2 microglia proliferation with interfering with cell cycle progression [26] . And it has also been investigated that AR enzyme inhibition 696 Natural Product Communications Vol. 13 (6) 2018 Cumaoğlu & Yerer has a crucial role in Aβ-induced neuroinflammation [23] . Apart from the studies that were included in this research the antiinflammatory role of quercetin and one of its derivatives MCPQ via AR inhibition even chemically or by silencing in Aβ induced neuroinflammation in microglial cells over NFκB/p65 translocation and MAPK/p38 pathways. In our study we have found that Q and MCPQ reduced these proinflammtory mediators via inhibiting the nuclear NFκB translocation and MAPK activity.
In another study, MCPQ, monoacetylferuloylquercetin (MAFQ) and chloronaphthoquinonequercetin (CHNQ) were shown to be better antioxidants compared to quercetin and showed a prominent inhibitory effect on aldose reductase and a-glucosidase. In the cellular models of BHNF-3 fibroblasts, microglial cell line BV-2, colorectal cancer cell lines HCT-116 and HT-29, CHNQ and MCPQ were studied for their cytotoxic, anti-proliferative and antiinflammatory properties [40] .
In this study, the anti-neuroinflammatory effects of two AR inhibitors, Q and MCPQ in an Aβ-induced microglial inflammation model was further explored to understand the potential of this mechanism. According to our results, AR inhibitors (Sorbinil, Q and MCPQ) significantly inhibit the protein expression of AR (Akr1b3) in microglial cells. Moreover, the silencing of AR with siRNA resulted in inhibition of the Aβ-induced COX2 expression revealing the relationship between inflammation and AR. We were also able to show that AR inhibitors (Sorbinil, Q and MCPQ) significantly inhibited the Aβ-induced the protein expression of TNF-α. The inhibitory effects of AR inhibitors especially Q on neuroinflammation mainly focused on two signaling pathways, that include NFκB/p65 translocation and MAPK. These results suggested that AR inhibitors (Q and MCPQ) were potent antiinflammatory active compounds which can be used as a therapeutic compounds against inflammation related diseases including neurodegeneration.
Experimental
Cell culture: Murine microglial cells (BV-2) from ATCC were grown in Dulbecco's modified Eagle's medium (DMEM; Hyclone, Waltham, MA, USA) supplemented with 10% heat-inactivated fetal bovine serum (FBS; Hyclone), 100 U/mL penicillin, and 100 μg/mL streptomycin and 2 mM glutamine at 37°C in a humidified incubator with 95 % air and 5 % CO 2 . [42] ), culture supernatants were exchanged with medium containing 0.5 mg/mL MTT for 4 h. The supernatant was removed and 100 μL dimethyl sulfoxide added. The absorbance was detected at 550 nm. The value of the control was set at 100 %. Quantitative Real-time PCR: BV-2 cells cultured in 6 well plate pretreatment with sorbinil, Q and MCPQ for 24 h followed by Aβ (5 µM) treatment (without phenol red, serum free medium) for 24 h. Total RNA isolated using RNAzol isolation reagent (SigmaAldrich, St. Louis, MO), according to the manufacturer's instructions. Total RNA (1 µg) was reverse-transcribed to cDNA using a Transcriptor High Fidelity cDNA Synthesis Kit (Roche Diagnostics GmbH, Mannheim, Germany). Real-time Polymer Chain Reaction (PCR) was carried out using a Light Cycler Nano System (Roche Diagnostics GmbH, Mannheim, Germany). To quantify cDNA, qPCR was performed using FastStart Essential DNA probe master mix (Roche Diagnostics GmbH, Mannheim, Germany) and catalogue assay kit (kits consist mix of primers and probes for determination of iNOS, COX2, β-actin). For each sample the level of target gene transcripts was normalized to β-actin.
Measurement of cell viability:
Western Blotting: After required pretreatments and treatments, BV-2 cells were lysed in 250 µL of RIPA lysis buffer (25 mM Tris (pH 7,4), 150 mM NaCl, 0.5 % sodium deoxycholate, 1 % NP-40) supplemented with protease inhibitor cocktail (Complete MiniTM, Roche, Mannheim, Germany) and 1 mM Na 3 VO 4 . Nuclear fractions were isolated using the NE-PER Nuclear and Cytoplasmic extraction reagents (Thermo Fisher Scientific, Rockford, IL, USA). Protein concentrations were determined by using the BCA protein assay (Pierce). 30 µg protein lysates were heated for 5 min at 94 °C in Laemmli sample buffer containing 4 % β-mercaptoethanol and loaded on 4-12 % Tris-glycine SDS-PAGE gels were then transferred electrophoretically to PVDF membranes. Membranes were incubated overnight at 4 °C with AR antibody (Akr1b3) COX2, iNOS (Santa Cruz Biotechnology CA, USA), anti-SAPK/JNK, phospho-SAPK/JNK (Thr183/Tyr185), anti-ERK, phospho-ERK (Thr202/Tyr204), anti-P38, phospho-P38 (Thr180/Tyr182) and anti-NFκB p65 antibodies (Cell Signaling Technology), protein bands were detected with horseradish peroxidase-conjugated secondary antibodies (Cell Signaling Technology) and visualized by West-Pico ECL reagents (Pierce).
ELISA (Enzyme-linked immunosorbent assay):
Mediums collected after pretreatment with sorbinil, Q and MCPQ for 24 h followed by Aβ treatment (without phenol red, serum free medium) for 24 h and assayed for cytokines (IFN-γ and TNF-α) and PGE 2 production using eBiosciences ELISA kits (San Diego, CA, USA) following the manufacturer's protocol to determine the proinflammatory and anti-inflammatory responses of the cells.
Nitric oxide (total nitrite-nitrate (NO x )) measurement: BV-2 cells were pretreated with sorbinil (10-40 µM), Q (2, 5-10 µM) and MCPQ (2,5-10 µM) for 24h and then treated with Aβ (5 µM) for 24h. Cell culture supernatants (50 μL) were collected and mixed with 100 μL of Griess reagent (1 % sulfanilamide/0.1 % naphthylethylene diamine dihydrochloride/2 % phosphoric acid). After incubation for 10 min, the optical density (OD) was measured at 540 nm. The concentrations of nitrite (a major stable product of NO) were calculated by reference to a standard curve generated by sodium nitrite in the assay according to the commercial kit procedure.
Statistical analysis: Possible associations between groups were analyzed with SigmaPlot 12 statistical software using student's ttest. P values <0,05 were considered as statistically significant. Fold increase or decrease of mRNA levels was also calculated by REST (relative expression software tool) software developed for groupwise comparison and statistical analysis of relative expression results.
